MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Cerrado

SectorSanidad

26.29 1.47

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

25.76

Máximo

26.34

Métricas clave
By Trading Economics
Ingresos	-85K 53M
Ventas	4.2M 153M
P/B Media del Sector	15.083 63.808
BPA	0.68
Margen de beneficios	34.53
Empleados	182
EBITDA	612K 81M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+33.26% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	151M 3.1B
Apertura anterior	24.82
Cierre anterior	26.29

Noticias sobre sentimiento de mercado

By Acuity

35%

65%

118 / 348 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 abr 2026, 20:26 UTC

Adquisiciones, fusiones, absorciones

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 abr 2026, 18:15 UTC

Noticias de Eventos Importantes

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 abr 2026, 16:49 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17 abr 2026, 16:49 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17 abr 2026, 22:58 UTC

Ganancias

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 abr 2026, 21:32 UTC

Charlas de Mercado

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 abr 2026, 21:22 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 abr 2026, 21:22 UTC

Charlas de Mercado

Moody's Downgrades Belgium to A1 -- Market Talk

17 abr 2026, 20:52 UTC

Ganancias

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 abr 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

17 abr 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 abr 2026, 20:29 UTC

Ganancias

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 abr 2026, 20:11 UTC

Adquisiciones, fusiones, absorciones

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 abr 2026, 19:34 UTC

Charlas de Mercado

Ganancias

Adquisiciones, fusiones, absorciones

Global Equities Roundup: Market Talk

17 abr 2026, 19:34 UTC

Charlas de Mercado

Ganancias

Adquisiciones, fusiones, absorciones

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 abr 2026, 19:31 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 abr 2026, 19:26 UTC

Charlas de Mercado

U.S. Natural Gas Futures Edge Up -- Market Talk

17 abr 2026, 19:21 UTC

Charlas de Mercado

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 abr 2026, 19:15 UTC

Charlas de Mercado

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 abr 2026, 19:07 UTC

Charlas de Mercado

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 abr 2026, 18:57 UTC

Noticias de Eventos Importantes

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 abr 2026, 18:53 UTC

Adquisiciones, fusiones, absorciones

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 abr 2026, 18:53 UTC

Adquisiciones, fusiones, absorciones

UCB 2026 Rev Guidance Unchanged

17 abr 2026, 18:52 UTC

Adquisiciones, fusiones, absorciones

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 abr 2026, 18:52 UTC

Adquisiciones, fusiones, absorciones

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 abr 2026, 18:14 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 abr 2026, 18:00 UTC

Noticias de Eventos Importantes

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 abr 2026, 18:00 UTC

Noticias de Eventos Importantes

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 abr 2026, 17:31 UTC

Charlas de Mercado

Noticias de Eventos Importantes

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 abr 2026, 17:26 UTC

Charlas de Mercado

Ganancias

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

33.26% repunte

Estimación a 12 Meses

Media 34.5 USD 33.26%

Máximo 35 USD

Mínimo 33 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

118 / 348 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.